Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL2204414 | 0.97 | — | — | |
| Water SCHEMBL1269330 | 0.82 | — | — | |
| Water SCHEMBL5322619 | 0.82 | — | — | |
| Dimethylformamide SCHEMBL3928720 | 0.81 | TSHR (0.39) | TSHR | |
| Methyl Alcohol SCHEMBL3869122 | 0.78 | — | — | |
| Propylene Glycol SCHEMBL2840491 | 0.78 | TDP1 (0.62) | TSHRALDH1A1LMNATDP1 | |
| SCHEMBL1153 | 0.78 | — | — | |
| SCHEMBL11615697 | 0.78 | — | — | |
| SCHEMBL5306546 | 0.78 | LMNA (0.31) | LMNA | |
| Ethylamine SCHEMBL11139919 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110291073-A | Heparanase inhibitors and application thereof | 贝塔医疗私人有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
| US-20160376240-A1 | 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use | ABBVIE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3097091-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015112445-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-7091234-B2 | Thio-oxindole derivatives | WYETH (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | disclosed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-6946454-B2 | Thio-oxindole derivatives | WYETH (US) | 2005-09-20 | — | — | US | disclosed |
| US-6841568-B2 | Thio-oxindole derivatives | WYETH (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | US | disclosed |
| US-20030225109-A1 | Thio-oxindole derivatives | WYETH (US) | 2003-12-04 | — | — | US | disclosed |
| US-6583145-B1 | Thio-oxindole derivatives | WYETH | 2003-06-24 | — | — | US | disclosed |
| US-20020169198-A1 | Thio-oxindole derivatives | WYETH (US) | 2002-11-14 | — | — | US | disclosed |
| US-6355648-B1 | COMPOUNDS AS CONTRACEPTIVES AND PROGESTERONE ANTAGONIST | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | NOS1, NOS3, NOS2 | TSHR 2049/4885ALDH1A1 1582/4885LMNA 3254/4885 |
| US-20160376240-A1 | 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use | MUSK, NTRK3, NTRK2 | TSHR 21/4885ALDH1A1 3074/4885LMNA 1373/4885 |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | TSHR 1545/4885ALDH1A1 651/4885LMNA 4685/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | TSHR 3442/4885ALDH1A1 2796/4885LMNA 3363/4885 |
| US-20030225109-A1 | Thio-oxindole derivatives | PGR, OXTR, PGRMC1 | TSHR 15/4885ALDH1A1 634/4885LMNA 4539/4885 |
| US-20020169198-A1 | Thio-oxindole derivatives | GPER1, PGR, ESR1 | TSHR 22/4885ALDH1A1 373/4885LMNA 4764/4885 |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | PDE5A, PDE3A, PDE2A | TSHR 3045/4885ALDH1A1 322/4885LMNA 1512/4885 |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | FGFR4, FGFR2, FGFR3 | TSHR 1545/4885ALDH1A1 651/4885LMNA 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.